Results Press Release for September 30, 2016
Natco Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended September 30, 201611-11-2016
11-11-2016
Outcome of Board Meeting
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 11, 2016, inter alia, has approved the following :1. Board allotted 1,33,555 (one lakh thirty three thousand five hundred fifty five) equity shares of Rs. 2/- each under Employee Stock option Scheme NATSOP2015 to the eligible employees of the Company.11-11-2016
Announces Q2 Results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended September 30, 2016
Natco Pharma Ltd has announced the following results for the quarter ended September 30, 2016:The Unaudited Standalone results for the Quarter ended September 30, 2016The Company has posted a net profit of Rs. 695.50 million for the quarter ended September 30, 2016 where as the same was at Rs. 343.20 million for the quarter ended September 30, 2015. Total Income is Rs. 4592.20 million for the quarter ended September 30, 2016 where...11-11-2016
Earnings call for the quarter results ended September 30, 2016
Natco Pharma Ltd has informed BSE regarding "Earnings call for the quarter results ended September 30, 2016".08-11-2016
Q2 results on Nov 11, 2016
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to beheld on November 11, 2016, inter alia, to consider, the Unaudited Financial Results for the quarter and half year endedSeptember 30, 2016, and related matters (Q2).Further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 Trading Window for dealing in the securities of the Company will be closed...01-11-2016
Shareholding for the Period Ended September 30, 2016
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here07-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Natco Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.07-10-2016
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Natco Pharma Ltd has informed BSE regarding the details of Voting results at the 33rd Annual General Meeting (AGM) of the Company held on September 30, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report and Proceedings of the Meeting in this regard.01-10-2016
Outcome of AGM
Natco Pharma Ltd has informed BSE that the 33rd Annual General Meeting (AGM) of the Company was held on September 30, 2016.30-09-2016
Presentation made to analysts /Investors
Natco Pharma Ltd has submitted to BSE a copy of Presentation made to analysts /Investors for the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2016.16-09-2016